The chemistry, radiochemistry, radiobiology, and radiopharmacology of
radiopharmaceuticals containing copper radionuclides are reviewed. Copper radionuclides …

The development of chelating agents for copper radionuclides in positron emission
tomography radiopharmaceuticals has been a highly active and important area of study in …

Molecular imaging is an important scientific discipline that plays a major role in clinical
medicine and pharmaceutical development. While several imaging modalities including X …

Copper-64 (T1/2= 12.7 hours; β+: 19%, β−: 38%) has a unique decay profile and can be
used for positron emission tomography imaging and radionuclide therapy. The well …

Copper is one of the most interesting elements for various biomedical applications. Copper
compounds show vast array of biological actions, including anti-inflammatory, anti …

There are several isotopes of copper and rhenium that are of interest in the development of
new molecular imaging or radiotherapeutic agents. This perspective article highlights the …

Highlights•Copper radionuclides for in vivo imaging of biological functions of copper
ions.•Copper-64 has suitable nuclear properties for cancer theranostics.•Radioactive copper …

The growing advancement in nuclear medicine challenges researchers from several
different fields to integrate imaging and therapeutic modalities in a theranostic …

Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron
emission tomography (PET) and single-photon imaging, including single-photon emission …

Summation Copper-64 (T1/2= 12.7 hours; β+, 0.653 MeV [17.8%]; β−, 0.579 MeV [38.4%])
has decay characteristics that allow for positron emission tomography (PET) imaging and …